FDA Launches 'TEMPO' Pilot Program to Revitalize Digital Therapeutics Market
The FDA's new TEMPO pilot allows prescribing digital therapeutics before clearance, using real-world data to inform approval. This offers a middle ground for DTx companies struggling with costly FDA pathways and reimbursement challenges, though Medicare coverage adoption remains below expectations.